Photo: Michael Ciaglo / Getty Images
Johnson & Johnson announced Tuesday that its COVID vaccine – 19 reaches a 94% effectiveness when a booster is given a few months after the original dose.
Johnson & Johnson’s one-shot vaccine, the company noted through a statement , has worked well in real patient studies, offers long-lasting protection against the virus and boosts the immune system.
When a booster was given two months after the first dose, the company said that the vaccine was 100% effective to protect COVID recipients – 19 severe and was 79% effective in preventing COVID – 19 symptomatic worldwide.
Was 94% effective at COVID prevention – 19 symptomatic in the United States, based on data presented.
The drug company made the announcement in a late stage clinical data release for the adenovirus-based vaccine, produced by Janssen, the Johnson & Johnson subsidiary , which received authorization for emergency use in the United States earlier this year.
Johnson & Johnson said they conducted two studies in which volunteers received a second dose of vaccine between two and six months after the first.
The boost led to an increase in the immune response in receptors between 18 and 55 years.
“When a COVID vaccine booster was administered – 19 from Johnson & Johnson two months after the first injection, antibody levels increased four to six times more than those seen after the single injection, “the pharmacist said in a statement.
In another study that tested a booster dose after six months, Johnson & Johnson said it observed increases in antibodies between nine and 12 times higher in the receivers.
The company also noted that one dose of the vaccine was shown to be 79% effective against infection in the United States between March and the end of July, and 81% effective in preventing hospitalization.
“There was no evidence of reduced effectiveness for the duration of the study, even when the Delta variant became dominant in the US,” he noted.
“Our vaccine a single injection generates strong immune responses and long-lasting immune memory and when a Johnson & Johnson COVID vaccine booster is given – 19, the strength of protection against COVID – 19 increases even more, ”the global director of Janssen said in a statement. Research and Development, Dr. Mathai Mammen.
Johnson & Johnson reported that it is in discussions with US and European regulators about possible booster doses.
Last week, the Food and Drug Administration recommended a booster of the Pfizer vaccine in Americans older than 65 years and those with the highest risk.
It may interest you Monoclonal antibodies, the popular alternative against COVID – 19 for those who do not want to be vaccinated
Moderna and Novavax are already working on a vaccine that combines COVID – 19 and influenza in a single injection
Modern vaccine protection against COVID – 19 lasts at least 6 months without needing reinforcement